Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors
- 1 March 2007
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (5) , 2178-2186
Abstract
The Affibody molecule ZHER2:342-pep2, site-specifically and homogeneously conjugated with a 1,4,7,10-tetra-azacylododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) chelator, was produced in a single chemical process by peptide synthesis. DOTA-ZHER2:342-pep2 folds spontaneously and binds HER2 with 65 pmol/L affinity. Efficient radiolabeling with >95% incorporation of 111In was achieved within 30 min at low (room temperature) and high temperatures (up to 90°C). Tumor uptake of 111In-DOTA-ZHER2:342-pep2 was specific for HER2-positive xenografts. A high tumor uptake of 23% injected activity per gram tissue, a tumor-to-blood ratio of >7.5, and high-contrast gamma camera images were obtained already 1 h after injection. Pretreatment with Herceptin did not interfere with tumor targeting, whereas degradation of HER2 using the heat shock protein 90 inhibitor 17-allylamino-geldanamycin before administration of 111In-DOTA-ZHER2:342-pep2 obliterated the tumor image. The present results show that radiolabeled synthetic DOTA-ZHER2:342-pep2 has the potential to become a clinically useful radiopharmaceutical for in vivo molecular imaging of HER2-expressing carcinomas. [Cancer Res 2007;67(5):2178–86]Keywords
This publication has 38 references indexed in Scilit:
- Breast imaging: a surgeon's prospectiveNuclear Medicine and Biology, 2005
- Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments forIn vivoImagingCancer Research, 2005
- Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastasesBJU International, 2005
- Quantitative Immuno-Positron Emission Tomography Imaging of HER2-Positive Tumor Xenografts with an Iodine-124 Labeled Anti-HER2 DiabodyCancer Research, 2005
- Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragmentsNuclear Medicine and Biology, 2005
- Somatostatin and Other Peptide Receptors as Tools for Tumor Diagnosis and TreatmentNeuroendocrinology, 2004
- Preclinical characterisation of 111In‐DTPA‐trastuzumabBritish Journal of Pharmacology, 2004
- A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient MiceCancer Research, 2004
- Fast and faster: A designed variant of the B‐domain of protein A folds in 3 μsecProtein Science, 2004
- Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distributionNuclear Medicine and Biology, 1999